Literature DB >> 2960766

The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.

A Kosugi1, T Yoshioka, T Suda, H Sano, Y Takahama, H Fujiwara, T Hamaoka.   

Abstract

The present study investigates the mechanisms of the recognition of tumor antigens by L3T4+ helper T cells responsible for the generation of Lyt-2+ cytotoxic T lymphocytes (CTL) against a major histocompatibility complex (MHC) Class II (Ia) antigen-negative syngeneic X5563 plasmacytoma. Treatment of X5563-immunized spleen cells with anti-L3T4 antibody plus complement (C) diminished the generation of Lyt-2+ anti-X5563 CTL. Since the contribution of L3T4+ cells was completely replaced by the addition of exogenous lymphokines, it was demonstrated that L3T4+ cells functioned as helper T cells assisting the generation of anti-X5563 CTL responses. Elimination of Ia-positive accessory cells (AC) from X5563-immunized spleen cells resulted in the abrogation of CTL generation, whereas the addition of exogenous lymphokines to AC-depleted X5563 immunized spleen cells restored the CTL response. The addition of anti-self Ia antibody to the culture also eliminated CTL responses. These observations demonstrated the requirement of Ia-positive AC for and the involvement of self Ia antigens in the activation of helper T cells. Moreover, use of tumor cells pretreated with paraformaldehyde to cultures of X5563-immunized spleen cells or adding back of AC pretreated with chloroquine to cultures of AC-depleted immune spleen cells failed to generate CTL responses. Finally, the addition of exogenous lymphokines to the above cultures resulted in appreciable restoration of CTL responses. Taken collectively, these results indicate that L3T4+ helper T cells are activated with tumor antigens processed and presented by Ia-positive AC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960766     DOI: 10.1002/jlb.42.6.632

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  12 in total

1.  Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells.

Authors:  J P Zou; J Shimizu; K Ikegame; H Takiuchi; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 2.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

3.  CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Authors:  D Mumberg; P A Monach; S Wanderling; M Philip; A Y Toledano; R D Schreiber; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

4.  Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice.

Authors:  Y Moriya; H Sato; K Ito; M Saito; T Yoshida; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

5.  The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: role of antigen-presenting cells and their surface class I and class II H-2 molecules.

Authors:  K Sakamoto; H Nakajima; J Shimizu; T Katagiri; C Kiyotaki; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Analysis of effector T cells against the murine syngeneic tumor MethA in mice orally administered antitumor polysaccharide SPR-901.

Authors:  Y Takeda; M Tanaka; H Miyazaki; S Takeo; K Nomoto; Y Yoshikai
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

7.  Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden.

Authors:  J P Zou; T Nagata; N Yamamoto; S Ono; H Fujiwara; T Hamaoka
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets.

Authors:  T Yoshioka; S Sato; M Ogata; K Sakamoto; H Sano; J Shima; H Yamamoto; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1988-01

9.  Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.

Authors:  K Sakamoto; T Yoshioka; J Shimizu; S Sato; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1988-01

10.  Suppression of anti-tumor CD4+ T cell responsiveness in the tumor-bearing state and its recovery in in vitro culture free of tumor burden.

Authors:  T Nagata; J P Zou; N Yamamoto; S Ono; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1993-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.